Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous DC Vaccine + Cabozantinib in Localized Clear Cell Renal Cancer
NCT05127824Phase 2Recruiting
- Start
- Jul 2023
- Primary completion
- Dec 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous alpha-DC1/TBVA vaccine in clear cell renal cell carcinoma (ccRCC) (2 arms). Primary endpoints: Probability of immune response at 48 months, Safety profile of interventional therapy - Adverse Events at 48 months and 2 more. Started Jul 2023; status: recruiting.
02
Drugs
autologous alpha-DC1/TBVA vaccine
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05127824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127824.